- Home
- BANC vs NVCR Comparison
BANC vs NVCR Comparison
Compare BANC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANC
- NVCR
- Stock Information
- Founded
- BANC 1941
- NVCR 2000
- Country
- BANC United States
- NVCR Switzerland
- Employees
- BANC N/A
- NVCR N/A
- Industry
- BANC Major Banks
- NVCR Medical/Dental Instruments
- Sector
- BANC Finance
- NVCR Health Care
- Exchange
- BANC Nasdaq
- NVCR Nasdaq
- Market Cap
- BANC 2.2B
- NVCR 1.9B
- IPO Year
- BANC N/A
- NVCR 2015
- Fundamental
- Price
- BANC $14.55
- NVCR $17.02
- Analyst Decision
- BANC Buy
- NVCR Buy
- Analyst Count
- BANC 11
- NVCR 7
- Target Price
- BANC $17.18
- NVCR $32.43
- AVG Volume (30 Days)
- BANC 2.3M
- NVCR 1.2M
- Earning Date
- BANC 07-23-2025
- NVCR 07-24-2025
- Dividend Yield
- BANC 2.74%
- NVCR N/A
- EPS Growth
- BANC N/A
- NVCR N/A
- EPS
- BANC 0.65
- NVCR N/A
- Revenue
- BANC $964,190,000.00
- NVCR $621,711,000.00
- Revenue This Year
- BANC $8.08
- NVCR $5.44
- Revenue Next Year
- BANC $10.50
- NVCR $9.05
- P/E Ratio
- BANC $22.42
- NVCR N/A
- Revenue Growth
- BANC 415.34
- NVCR 18.27
- 52 Week Low
- BANC $11.52
- NVCR $14.17
- 52 Week High
- BANC $18.08
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- BANC 61.93
- NVCR 47.92
- Support Level
- BANC $14.53
- NVCR $17.33
- Resistance Level
- BANC $15.34
- NVCR $18.59
- Average True Range (ATR)
- BANC 0.31
- NVCR 0.69
- MACD
- BANC 0.07
- NVCR 0.01
- Stochastic Oscillator
- BANC 69.23
- NVCR 31.44
About BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.